Monthly update of U.S. Food and Drug Administration (FDA) approvals impacting the workers' compensation industry. myMatrixx's report includes new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and newly available generics in the last 12 months.
Monthly Drug News
Accord Pharmaceuticals announced on June 8, 2022, that its vilazodone tablets, 10mg, 20mg and 40mg, are ready to ship in the United States, but pricing was not disclosed. The generic for Viibryd® (Allergan), vilazodone is taken once a day for treating adult patients who have major depression. Other manufacturers have FDA approval for generics, as well, but no information is available about their possible launches. Under a settlement agreement, some of the companies will share 180-day exclusivity.
Impact to Workers’ Comp
While antidepressants may have a role in a workers’ compensation injury, Viibryd has not historically been heavily utilized, so the impact of this new generic will be relatively limited. For any questions about the use of Viibryd, antidepressants and potential relatedness to a claim, please consult with your myMatrixx pharmacist.